# KingstronBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kingstronbio

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.kingstronbio.com
- Total disclosed funding: $67M
- Latest round: Series C (Nov 19, 2021)
- Investors on record: 9

## About

Based in Changshu, China and established in 2012, KingStronBio is a medical device company that is R&D, and production of cardiovascular device. The company covered more than 20 acres, which factory integrated R&D and production has been built and put into use, and is building high-end cardiovascular device manufacture base. 

The company provides products include surgical biological valves, valvulopasty rings, biological patches, interventional mitral valves, interventional tricuspid valves, transcatheter aortic valve implantation (TAVR). Up to 2021, The surgical line valve forming ring, and surgical bioprosthetic valve products have been sold. The third generation transcatheter aortic valve system is about to complete clinical trials.

The company plans to promote the development of mitral and tricuspid valves products, and registration of third-generation TAVR products. Also, it will mass production of surgical biological valves, biological patches.

## Funding rounds

- Series C, Nov 19, 2021, $47M — Hong Shan, Everbright Financial Capital, Panlin Capital, GF Qianhe
- Series B, Jan 22, 2018, $20M — Coastal Capital, Salubris
- Series A, Mar 5, 2016 — Cowin Capital, YuanBio Venture, Coastal Capital, Tengye Ventures

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Coastal Capital (https://capitalatlas.ai/funds/coastal-capital) — Series A, Series B
- Tengye Ventures (https://capitalatlas.ai/funds/tengye-ventures) — Series A
- Salubris — Series B
- Hong Shan — Series C
- Everbright Financial Capital (https://capitalatlas.ai/funds/everbright-financial-capital) — Series C
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series C
- GF Qianhe — Series C